source
- Moderna and Merck report success for personalized mRNA vaccine in late-stage melanoma trialModerna and Merck announced that their personalized mRNA cancer vaccine succeeded in a late-stage melanoma study. The vaccine, called intismeran, was evaluated in a randomized Phase 3 trial, the fi…
- Moderna cancer vaccine data lifts investor confidence, shares jump to multi-year highsModerna has long said it wants to broaden its portfolio beyond infectious-disease vaccines. The company has been working on a cancer vaccine and investors have been waiting for late-stage trial res…